JP2008508885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508885A5 JP2008508885A5 JP2007525033A JP2007525033A JP2008508885A5 JP 2008508885 A5 JP2008508885 A5 JP 2008508885A5 JP 2007525033 A JP2007525033 A JP 2007525033A JP 2007525033 A JP2007525033 A JP 2007525033A JP 2008508885 A5 JP2008508885 A5 JP 2008508885A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- use according
- group
- antigen
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 claims 26
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 claims 26
- 239000012634 fragment Substances 0.000 claims 23
- 206010052779 Transplant rejections Diseases 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 8
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000012657 Atopic disease Diseases 0.000 claims 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 3
- 230000002917 arthritic effect Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59908604P | 2004-08-05 | 2004-08-05 | |
| US63917604P | 2004-12-23 | 2004-12-23 | |
| PCT/US2005/027912 WO2006135385A2 (en) | 2004-08-05 | 2005-08-05 | Antagonizing interleukin-21 receptor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508885A JP2008508885A (ja) | 2008-03-27 |
| JP2008508885A5 true JP2008508885A5 (https=) | 2008-09-04 |
Family
ID=37309615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525033A Withdrawn JP2008508885A (ja) | 2004-08-05 | 2005-08-05 | インターロイキン−２１受容体活性を中和すること |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20060039902A1 (https=) |
| EP (1) | EP1773394A2 (https=) |
| JP (1) | JP2008508885A (https=) |
| KR (1) | KR20070057789A (https=) |
| AR (1) | AR051071A1 (https=) |
| AU (1) | AU2005332996A1 (https=) |
| BR (1) | BRPI0514138A (https=) |
| CA (1) | CA2574848A1 (https=) |
| CR (1) | CR8891A (https=) |
| EC (1) | ECSP077226A (https=) |
| IL (1) | IL181044A0 (https=) |
| MX (1) | MX2007001509A (https=) |
| NO (1) | NO20070973L (https=) |
| RU (1) | RU2007102287A (https=) |
| TW (1) | TW200608995A (https=) |
| WO (1) | WO2006135385A2 (https=) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110075507A1 (en) * | 1997-10-24 | 2011-03-31 | Revalesio Corporation | Diffuser/emulsifier |
| US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
| NZ542306A (en) | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
| CA2518854A1 (en) * | 2003-03-21 | 2004-10-07 | Wyeth | Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor |
| CN101160528A (zh) | 2005-02-14 | 2008-04-09 | 惠氏公司 | Il17-f在诊断和治疗气道炎症中的用途 |
| GT200600065A (es) * | 2005-02-14 | 2006-10-02 | Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos | |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| CA2604222A1 (en) | 2005-04-18 | 2006-10-26 | Novo Nordisk A/S | Il-21 variants |
| WO2007043641A1 (ja) * | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
| AR058135A1 (es) * | 2005-10-21 | 2008-01-23 | Chugai Pharmaceutical Co Ltd | Agentes para el tratamiento de cardiopatias |
| AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| TW200803894A (en) * | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
| WO2007114861A2 (en) * | 2005-11-28 | 2007-10-11 | Zymogenetics, Inc. | Il-21 receptor antagonists |
| WO2007111714A2 (en) * | 2005-11-28 | 2007-10-04 | Zymogenetics, Inc. | Il-21 antagonists |
| AU2007208678B2 (en) * | 2006-01-27 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for diseases involving choroidal neovascularization |
| JP5754875B2 (ja) * | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
| US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
| US8609148B2 (en) * | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| CA2667791A1 (en) | 2006-10-25 | 2008-05-02 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
| JP5306214B2 (ja) * | 2006-10-25 | 2013-10-02 | リバルシオ コーポレイション | 混合装置 |
| EP2083876A4 (en) * | 2006-10-25 | 2012-09-19 | Revalesio Corp | WOUND CARE AND TREATMENT METHOD |
| JP2010507382A (ja) | 2006-10-26 | 2010-03-11 | ノヴォ ノルディスク アクティーゼルスカブ | Ｉｌ−２１変異体 |
| US8211420B2 (en) | 2006-12-21 | 2012-07-03 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the IL-21 receptor |
| TWI438208B (zh) * | 2007-01-23 | 2014-05-21 | 中外製藥股份有限公司 | 抑制慢性排斥反應之藥劑 |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| US9745567B2 (en) * | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US20100303918A1 (en) * | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
| US20100029764A1 (en) * | 2007-10-25 | 2010-02-04 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| US20100015235A1 (en) * | 2008-04-28 | 2010-01-21 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US20090263495A1 (en) * | 2007-10-25 | 2009-10-22 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| US10125359B2 (en) * | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| WO2009055620A1 (en) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| US20100009008A1 (en) * | 2007-10-25 | 2010-01-14 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| US20100303871A1 (en) * | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| WO2010062628A1 (en) * | 2008-10-27 | 2010-06-03 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
| US20100303917A1 (en) * | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for treating cystic fibrosis |
| US20090227018A1 (en) * | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| US7883700B2 (en) | 2007-12-07 | 2011-02-08 | Zymogenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| CA2716801A1 (en) * | 2008-03-12 | 2009-09-17 | Wyeth Llc | Methods for identifying cells suitable for large-scale production of recombinant proteins |
| WO2009132821A1 (en) * | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
| CA2723215A1 (en) * | 2008-05-01 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| US8178097B2 (en) * | 2008-05-23 | 2012-05-15 | Wyeth Llc | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
| PE20100141A1 (es) * | 2008-05-23 | 2010-02-22 | Wyeth Corp | Proteina de union al receptor de interleuquina 21 |
| CA2728243C (en) * | 2008-06-05 | 2020-03-10 | Chugai Seiyaku Kabushiki Kaisha | Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer |
| US20100075329A1 (en) * | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
| CA2740077A1 (en) | 2008-10-08 | 2010-04-15 | Cambridge Enterprise Limited | Methods and compositions for diagnosis and treatment |
| US20100098659A1 (en) * | 2008-10-22 | 2010-04-22 | Revalesio Corporation | Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| ES2616086T3 (es) * | 2009-08-17 | 2017-06-09 | A & G Pharmaceutical, Inc. | Materiales y procedimientos para el desarrollo de un estado de no respuesta inmune específica de antígeno |
| KR101004363B1 (ko) * | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제 |
| WO2011119404A1 (en) * | 2010-03-26 | 2011-09-29 | Monsanto Technology Llc | Portable systems and methods for amplifying nucleotides and detecting nucleotide sequences |
| CN104983740A (zh) | 2010-05-07 | 2015-10-21 | 利发利希奥公司 | 用于增强生理性能和恢复时间的组合物和方法 |
| WO2011149051A1 (ja) | 2010-05-28 | 2011-12-01 | 中外製薬株式会社 | 抗腫瘍t細胞応答増強剤 |
| WO2012012531A2 (en) * | 2010-07-20 | 2012-01-26 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods featuring il-6 and il-21 antagonists |
| JP2013533320A (ja) | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
| EP2665486B1 (en) | 2011-01-18 | 2019-12-25 | Bioniz, LLC | Compositions for modulating gamma-c-cytokine activity |
| KR20130011056A (ko) * | 2011-07-20 | 2013-01-30 | 주식회사에이앤알쎄라퓨틱스 | 염증표적 수용체 및 염증 질환 치료용 약물 운반체 |
| ES2685076T3 (es) * | 2011-08-30 | 2018-10-05 | Abb Schweiz Ag | Transformador de tipo seco |
| US20150030562A1 (en) * | 2011-12-23 | 2015-01-29 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of treating or preventing viral diseases by blocking interleukin-21 |
| US20160215042A1 (en) * | 2013-04-19 | 2016-07-28 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
| US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
| AU2015244025B2 (en) | 2014-04-08 | 2019-03-21 | Boston Pharmaceuticals Inc. | Binding molecules specific for IL-21 and uses thereof |
| US10662240B2 (en) * | 2014-12-19 | 2020-05-26 | Mabtech Ab | Composition, kit and method for inhibition of IL-21 mediated activation of human cells |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| AU2016341529B2 (en) | 2015-10-22 | 2023-03-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| WO2018013585A1 (en) * | 2016-07-12 | 2018-01-18 | Flagship Pioneering, Inc. | Methods and compositions for modulating thymic function |
| WO2018038898A2 (en) * | 2016-08-05 | 2018-03-01 | The Regents Of The University Of California | Mithrene and methods of fabrication of mithrene |
| US12600757B2 (en) | 2017-04-07 | 2026-04-14 | Bioniz Therapeutics, Inc. | Peptides inhibiting gamma-c-cytokine activity and methods of use |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| JP7235249B2 (ja) | 2017-10-20 | 2023-03-08 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| EP3957324A4 (en) | 2019-04-17 | 2023-02-08 | Hiroshima University | THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR |
| CN110124029B (zh) * | 2019-04-19 | 2023-08-11 | 中山大学附属第六医院 | Il-6r抗体及羊水干细胞在制备用于治疗nec的药物中的应用 |
| CA3137971A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| JP2023549293A (ja) * | 2020-10-26 | 2023-11-22 | ネプチューン バイオサイエンシズ エルエルシー | 直交ｉｌ－２１受容体／サイトカイン系 |
| CN119020389A (zh) * | 2024-08-26 | 2024-11-26 | 江苏省人民医院（南京医科大学第一附属医院） | 一种具备il-6r纳米抗体分泌功能的重组枯草芽孢杆菌及其构建方法和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US425871A (en) * | 1890-04-15 | Half to james l | ||
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) * | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) * | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| MX336813B (es) * | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| US6350892B1 (en) * | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| ES2279809T3 (es) * | 2000-04-05 | 2007-09-01 | Zymogenetics, Inc. | Receptores de citoquina zalfa11 solubles. |
| ES2629395T3 (es) * | 2001-10-04 | 2017-08-09 | Genetics Institute, Llc | Métodos y composiciones para modular la actividad de la interleucina-21 |
| WO2003087320A2 (en) * | 2002-04-09 | 2003-10-23 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| US7314623B2 (en) * | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
| NZ542306A (en) * | 2003-03-14 | 2008-04-30 | Wyeth Corp | Antibodies against human IL-21 receptor and uses therefor |
| CA2518854A1 (en) * | 2003-03-21 | 2004-10-07 | Wyeth | Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor |
| EP1753458A4 (en) * | 2004-05-19 | 2009-07-22 | Wyeth Corp | MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis |
-
2005
- 2005-08-05 RU RU2007102287/13A patent/RU2007102287A/ru not_active Application Discontinuation
- 2005-08-05 EP EP05857905A patent/EP1773394A2/en not_active Withdrawn
- 2005-08-05 US US11/197,488 patent/US20060039902A1/en not_active Abandoned
- 2005-08-05 AU AU2005332996A patent/AU2005332996A1/en not_active Abandoned
- 2005-08-05 WO PCT/US2005/027912 patent/WO2006135385A2/en not_active Ceased
- 2005-08-05 JP JP2007525033A patent/JP2008508885A/ja not_active Withdrawn
- 2005-08-05 BR BRPI0514138-9A patent/BRPI0514138A/pt not_active IP Right Cessation
- 2005-08-05 CA CA002574848A patent/CA2574848A1/en not_active Abandoned
- 2005-08-05 AR ARP050103287A patent/AR051071A1/es unknown
- 2005-08-05 MX MX2007001509A patent/MX2007001509A/es not_active Application Discontinuation
- 2005-08-05 KR KR1020077002877A patent/KR20070057789A/ko not_active Withdrawn
- 2005-08-08 TW TW094126735A patent/TW200608995A/zh unknown
-
2007
- 2007-01-29 IL IL181044A patent/IL181044A0/en unknown
- 2007-02-01 CR CR8891A patent/CR8891A/es not_active Application Discontinuation
- 2007-02-05 EC EC2007007226A patent/ECSP077226A/es unknown
- 2007-02-21 NO NO20070973A patent/NO20070973L/no not_active Application Discontinuation
- 2007-11-29 US US11/947,425 patent/US20080241098A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508885A5 (https=) | ||
| RU2007102287A (ru) | Антагонисты активности рецептора интерлейкина-21 | |
| JP2021536237A5 (https=) | ||
| CN102307896B (zh) | 基于iii型纤连蛋白结构域的支架组合物、方法及用途 | |
| JP2021520374A (ja) | 移植可能な粒子及び関連方法 | |
| JP2014530611A5 (https=) | ||
| JP2020534837A (ja) | 活性細胞を含む方法、組成物、及び移植可能な要素 | |
| WO2010055366A4 (en) | Anti-human il-21 monoclonal antibodies | |
| CN106188297B (zh) | 抗CTLA-4的纳米抗体Nb91及其制备方法与应用 | |
| JP2016518823A5 (https=) | ||
| JP2012507994A (ja) | Ｈｌａ−ｇタンパク質及びその薬学的使用 | |
| JP2010500005A5 (https=) | ||
| EP1299522B1 (en) | Alteration of cell membrane | |
| CN115028719B (zh) | 血清白蛋白结合纳米抗体及其制备方法与应用 | |
| CN106046164B (zh) | 抗CTLA-4的纳米抗体Nb36及其制备方法与应用 | |
| EP2566500B1 (en) | Ccl1 for use in therapy | |
| CN117866904A (zh) | 基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途 | |
| JP2025521602A (ja) | 炎症状態および自己免疫状態を処置するための方法および組成物 | |
| CN112805302B (zh) | 抗BCMA单链抗体scFv及其制备方法和应用 | |
| CN109897107A (zh) | 纳米抗体及其制备方法 | |
| CN104017088A (zh) | 双功能修饰铁蛋白重链亚基纳米粒子及其制备方法和用途 | |
| CN118184786B (zh) | 一种靶向gpc3的鲨鱼单域抗体vnar-f10及其应用 | |
| CN104725514A (zh) | 新型il23拮抗剂 | |
| CN101407546B (zh) | 全人源抗人肿瘤坏死因子-α单链抗体 | |
| JP2025521755A (ja) | 共有結合架橋多糖及びその使用方法 |